disease
-
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
Alzheimer’s & Dementia Care
The Relentless Unraveling: Navigating the Complexities of Alzheimer’s Disease
Alzheimer’s disease is often described as a long farewell—a relentless unraveling of memory, identity, and connection, presenting a profound and…
Read More » -
Alzheimer’s & Dementia Care
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More » -
Palliative & Hospice Care
Alzheimer’s Disease, Amyloid, and Antibodies: Experts Grapple with Evolving Definitions and Treatment Dilemmas
The landscape of Alzheimer’s disease diagnosis and treatment is undergoing a profound transformation, driven by advancements in understanding the disease’s…
Read More » -
Alzheimer’s & Dementia Care
Blarcamesine Demonstrates Sustained Efficacy Over Three Years in Early Alzheimer’s Disease, Offering Hope for Disease Modification
Copenhagen, Denmark – In a significant development for Alzheimer’s disease research, Anavex Life Sciences has announced that the therapeutic benefits…
Read More » -
Alzheimer’s & Dementia Care
Researchers Urge More Studies on Lymphovenous Anastomosis (LVA) for Alzheimer’s Disease, Citing Potential for Brain Waste Clearance
A cohort of researchers is advocating for extensive studies into whether lymphovenous anastomosis (LVA), a surgical intervention designed to facilitate…
Read More »